---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015429"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:01:15.699995+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Passage Bio Q3 net loss $19.3M; 4 patients enrolled in FTD-GRN Cohort 2; cash to Q2 2026

## Summary
- Net loss $19.3M ($0.31/share) vs $27.1M loss a year ago; R&D expenses fell to $8.7M from $15.1M.
- Cash and securities $84.8M at Sept 30, 2024; expected runway to end Q2 2026.
- Enrolled 4 patients in Cohort 2 of upliFT-D trial; 12-month Cohort 1 and interim Cohort 2 data due 1H25.
- Interim Cohort 1 data: PBFT02 raised CSF progranulin for up to 12 months; no serious adverse events with enhanced immunosuppression.
- Appointed Tom Kassberg (Ultragenyx CBO) to board of directors and Audit Committee.

## SEC filing metadata
- accession: 0001558370-24-015429
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837024015429/0001558370-24-015429-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837024015429/pasg-20241113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015429
- JSON: https://secwatch.observer/filing/0001558370-24-015429.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015429.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.